Yvonne A. Efebera

Widespread Genetic Heterogeneity in Multiple Myeloma: Implications for Targeted Therapy

Jens G. Lohr, Petar Stojanov, Scott L. Carter et al. · Cancer Cell · 2014 · 1K citations · Full text

Medicine, Hematology, Molecular Genetics +16

International, Multicenter Standardization of Acute Graft-versus-Host Disease Clinical Data Collection: A Report from the Mount Sinai Acute GVHD International Consortium

Andrew C. Harris, Rachel Young, Steven M. Devine et al. · Biology of Blood and Marrow Transplantation · 2015 · 960 citations · Full text

Life Sciences, Hematology, Immunology +11

The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti–PD-1 antibody

Don M. Benson, Courtney E. Bakan, Anjali Mishra et al. · Blood · 2010 · 801 citations · Full text

Medicine, Immunology, Oncology +17

Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial

Peter M. Voorhees, Jonathan L. Kaufman, Jacob P. Laubach et al. · Blood · 2020 · 690 citations · Full text

Medicine, Oncology, Pharmacotherapy +14

Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis

Javier Bolaños‐Meade, Mehdi Hamadani, Juan Wu et al. · New England Journal of Medicine · 2023 · 547 citations · Full text

Pharmacy, Hematology, Pharmacotherapy +16